2023-03-30 09:32:48 ET
- Akari Therapeutics ( NASDAQ: AKTX ) entered into definitive agreements with certain institutional investors and accredited investors which also includes board members, and President and CEO Rachelle Jacques.
- Gross proceeds are expected to be ~$4M through the issuance of ~26.7M registered ADSs at a purchase price of $0.15/ADS wherein one ADS represents 100 ordinary shares, par value $0.0001 per share, in a registered direct offering.
- Offering is expected to take place on or about Mar.31, 2023.
- Net proceeds are expected to support advancement of Akari’s two priority pipeline programs investigating nomacopan, a bispecific recombinant inhibitor of complement C5 and leukotriene B4.
For further details see:
Akari Therapeutics to raise $4M in stock offering